BACKGROUND Allogeneic adsorption (alloadsorption) involves incubating an aliquot of patient plasma with red blood cells (RBCs) of a known phenotype to facilitate removal of autoantibodies and allow for detection of remaining, potentially clinically significant alloantibodies. Alloadsorptions are routinely performed using fresh or frozen donor RBCs having particular Rh and Kidd phenotypes, and are usually enzyme or ZZAP treated before adsorptions. RBC stroma would provide a method to prepare large amounts of adsorption material that may be stored frozen and used when needed. STUDY DESIGN AND METHODS A total of 309 samples were presented to our institutions (American Red Cross, Southwest Region Texas laboratories) with serologic positive IgG autoantibodies, had allogeneic RBC stromal adsorptions performed, and underlying alloantibodies identified. After papain treatment of RBCs from group O, K- individuals who were R1 R1 , R2 R2 , and rr where at least one individual was Jk(a+b-) and one individual Jk(a-b+), stroma was prepared using digitonin digestion of the RBC membrane. Large amounts of stroma could be obtained and were aliquoted and frozen at -18°C or less for up to 2 years. RESULTS One hundred seventeen of 309 (38%) samples demonstrated alloantibodies following stromal alloadsorptions. Twenty-two different alloantibodies were identified in the stroma-adsorbed plasma, with an average of two stromal adsorptions resolving the autoantibody reactivity. The specificities of alloantibodies underlying the autoantibody included those in the Rh system (112), Kell system (24), Duffy system (14), Kidd system (30), MNS system (19), Lutheran system (2), and Diego system (2). CONCLUSION Successful removal of autoantibody using RBC stromal adsorption was obtained in 308 samples and allowed for the identification of underlying alloantibodies in 117 samples. Preparation and use of RBC stroma should significantly benefit immunohematology reference laboratories in their antibody investigations.

中文翻译：

---

人类红细胞基质：是传统同种异体吸附方法的替代方法。

背景技术同种异体吸附（吸附吸附）涉及将患者血浆的等分试样与已知表型的红细胞（RBC）一起孵育，以促进自身抗体的去除并允许检测剩余的，潜在的临床上重要的同种抗体。通常使用具有特定Rh和Kidd表型的新鲜或冷冻的供体RBC进行上清吸附，并且通常在吸附前用酶或ZZAP处理。RBC基质将提供一种制备大量吸附材料的方法，这些材料可以冷冻保存并在需要时使用。研究设计和方法共有309份样本被送至我们的机构（美国红十字会，德克萨斯州西南地区实验室），这些样本具有血清学阳性IgG自身抗体，进行了同种异体RBC基质吸附，并鉴定出潜在的同种抗体。用木瓜蛋白酶处理O组，R1 R1，R2 R2和rr的K-个体（其中至少一个个体为Jk（a + b-）和一个个体Jk（a-b +））的RBC后，使用洋地黄皂苷制备基质红细胞膜的消化。可以获得大量基质，将其等分并在-18°C或更低的温度下冷冻长达2年。结果309个样本中有117个（38％）在基质上清过程中表现出同种抗体。在基质吸附血浆中鉴定出22种不同的同种抗体，平均两种基质吸附可分辨自身抗体反应性。自身抗体基础的同种抗体的特异性包括Rh系统（112），Kell系统（24），Duffy系统（14），Kidd系统（30），MNS系统（19），Lutheran系统（2）和Diego系统中的那些（2）。结论在308个样品中使用RBC基质吸附成功去除了自身抗体，并鉴定了117个样品中的潜在同种抗体。红细胞基质的制备和使用应在免疫血液学参考实验室的抗体研究中显着受益。